Hemostemix Inc

As of June 30, 2026, Hemostemix Inc carries a market capitalization of 10.25M, placing it among publicly traded companies globally. Its enterprise value stands at 13.62M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hemostemix Inc's next confirmed earnings release is scheduled for November 27, 2026.

As of June 30, 2026, Hemostemix Inc has 205.00M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Hemostemix Inc maintains a current ratio of 0.13, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -61.85, indicating conservative leverage, while an interest coverage ratio of -17.60 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -767.40, reflecting losses generated across the asset base.

As of the close on September 23, 2026, Hemostemix Inc's stock has declined approximately 30.00% over the past 52 weeks. The 50-day moving average sits at 0.09, while the 200-day moving average is 0.12.

Over the twelve months ended June 30, 2026, Hemostemix Inc generated - - in revenue and converted that into -4.54M in net income, yielding earnings per share of -0.03. EBITDA reached -4.16M, while operating income came in at -5.79M.

As of June 30, 2026, Hemostemix Inc holds 196,459.00 in cash and equivalents against 3.56M in total debt, resulting in a net debt position of 3.43M. Total book value stands at -5.76M, with working capital of -1.71M providing operational flexibility.

Hemostemix Inc produced -5.27M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -59.33: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -46.12, meaning Hemostemix Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Hemostemix Inc's most recent stock split took place on December 30, 2020 with a 20:1 split ratio.

As of June 30, 2026, Hemostemix Inc has an Altman Z-Score of -473.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.